Carcinogenesis Advance Access published online on September 7, 2007
Carcinogenesis, doi:10.1093/carcin/bgm191
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
MDM2 SNP309 and Cancer Risk: A Combined Analysis
1 Department of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
2 Center for Family and Community Medicine, Karolinska Institute, SE-14183 Huddinge, Sweden
* Corresponding author: German Cancer Research Center (DKFZ), Genomic Epidemiology, Im Neuenheimer Feld 580, 69120 Heidelberg, Germany, Tel.: 6221-421792, Fax: 6221-421810, E-mail: stefan_wilkening{at}web.de
A paper by Bond et al. reported that a single nucleotide polymorphism (SNP) in the intronic promoter region of the MDM2 gene (called SNP309) can significantly change the expression of MDM2 and thereby suppress the p53 pathway. Furthermore, it was shown that SNP309 accelerates tumor formation in Li-Fraumeni patients. This initial report aroused the attention of many researchers, which investigated the role of SNP309 for the risk and the onset of cancer in different tissues. To provide a more robust estimate of the effect of this polymorphism on cancer risk, we combined the available genotype data for breast, colorectal, and lung cancers. For breast cancer, we combined the data from 11 studies including 5737 cases and 6703 controls. For colorectal cancer, we combined the data from five studies 1620 cases and 886 controls. For lung cancer, we performed a fixed-effect meta-analysis from seven studies including 4276 cases and 5318 controls. Our results suggest that the SNP309 variant does not have an impact on the risk of breast (OR 0.97, 95% CI 0.87-1.08) or colorectal cancers (OR 0.97, 95% CI 0.76-1.25). However, the combined estimate of the ORs for lung cancer revealed an increased risk for GG versus TT (OR 1.27, 95% CI 1.12-1.44). The data show that SNP309 alone has little or no effect on the risk of common cancers, but it might modify the time of tumor onset and prognosis.
Key Words: MDM2 • single nucleotide polymorphism • promoter • cancer • meta-analysis
Received June 28, 2007; revised August 14, 2007; accepted August 14, 2007.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. Zenz, S. Habe, A. Benner, D. Kienle, H. Dohner, and S. Stilgenbauer The MDM2 -309 T/G promoter single nucleotide polymorphism does not alter disease characteristics in chronic lymphocytic leukemia Haematologica, July 1, 2008; 93(7): 1111 - 1113. [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Dong, J. D. Potter, E. White, C. M. Ulrich, L. R. Cardon, and U. Peters Genetic Susceptibility to Cancer: The Role of Polymorphisms in Candidate Genes JAMA, May 28, 2008; 299(20): 2423 - 2436. [Abstract] [Full Text] [PDF]
|
|